Webinars & Videos
Featured
In the first webinar of NFXF’s 2026 Webinar Series, we hear updates from each of the current NIH-funded Fragile X Centers of Excellence. This funding remains critical to sustaining progress and advancing future discoveries.
Latest
This session reviews features of attention problems, hyperactivity, and impulsivity in FXS and reviews previous studies of ADHD in Fragile X.
Barbara Haas-Givler and Cora Taylor discuss executive functioning in individuals with both the Fragile X full mutation and the premutation, including what executive function is and strategies to support individuals.
All Webinars and Videos
Dr. David Hessl joined the NFXF to discuss the exciting new ACT for FXTAS study, funded by the National Institute of Neurological Disorders and Stroke (NINDS).
Two FXTAS videos from two Fragile X experts. Dr. Peter Todd gives an overview of the causes and symptoms of FXTAS, the typical diagnostic journey for those affected, and what to expect for clinical care. Dr. David Hessl gives an overview of the current state of research and drug development related to FXTAS.
Dr. Hessl discusses the details of a longitudinal study that examined executive functioning changes in men living with the FMR1 premutation. He describes how the study was conducted, what the results showed, why they are important, what they mean for the FX community, and the next steps to move us forward.
This one-hour moderated Q&A session discussed the Fragile X–Associated Tremor/Ataxia Syndrome (FXTAS) diagnostic criteria, common symptoms, strategies and treatments to manage the effects of FXTAS, and the importance of research. While there is no cure for FXTAS, there has been positive progress in clinical care and treatment, providing hope for the future.
Patients, caregivers, junior researchers, and others may benefit from the material in this presentation from Dr. Deborah Hall, neurologist and professor at the Rush Medical College Department of Neurological Sciences. Dr. Hall has treated FXTAS patients over the last two decades.
This study presents the pathological progression of several longitudinally followed patients with FXTAS at the UC Davis Fragile X Research and Treatment Center. Standardized clinical, neuropsychological, and molecular assessments over the last 10 years will be discussed. Some patients showed an early-onset and fast FXTAS progression, others showed a late-onset and slow FXTAS progression of symptoms of neurodegeneration that might point to a diverse concept of pathogenesis in FXTAS.
Each of the panelists answer questions from their experiential perspectives on topics related to the Fragile X premutation, including FXTAS, FXPOI, and other emerging areas of concern.
An expert panel discusses FXTAS, which occurs in premutation carrier men and women when they are over the age of 55. It is associated with tremors, balance problems, and other neurological signs. The expert panel answers questions from caregivers, clinicians, researchers, and of course FXTAS patients.
Fragile X-associated Tremor/Ataxia Syndrome (FXTAS) can occur in individuals with the Fragile X Premutation. It is an “adult-onset” neurodegenerative disorder, more common in males than females over 50 years of age. FXTAS is associated with tremors, balance problems, and other neurological signs.